Appclon announced on the 31st that its chimeric antigen receptor T-cell (CAR-T) therapy 'AT101' has received New Excellent Technology (NET) certification from the Korea Industrial Technology Association. This is the first case of a CAR-T therapy technology receiving NET certification.


AT101 is being developed to overcome patient non-responsiveness and relapse suppression compared to existing therapies. To achieve this, it applies △ a novel epitope-binding antibody that targets a different action site on disease proteins to respond even in non-responsive patients △ an antibody with a new concept of dissociation (Fly-kiss) characteristics that can maximize the anticancer activity of CAR-T therapies. This enables maximization of therapeutic effects and securing sustained anticancer efficacy.


This therapy targets diffuse large B-cell lymphoma. It utilizes the humanized antibody 'h1218' developed in-house through the new antibody development platform 'NEST'. Currently, it is undergoing Phase 2 clinical trials.


Appclon's independently developed NEST platform is an antibody development technology that discovers everything from antigen selection to antigen-binding sites (epitopes). This platform can be applied to all antibody-based therapies.


A company representative stated, "With this NET certification, the innovation of antibody development technology including CAR-T therapy development technology has been recognized," adding, "We will accelerate the development of treatments for intractable cancers through new antibody development based on the NEST platform."



The 'New Excellent Technology' certification system, jointly operated by the Ministry of Trade, Industry and Energy's National Institute of Technology and Standards and the Korea Industrial Technology Association, designates outstanding performance, technology, and products as excellent products. Priority supply to various demand institutions through negotiated contracts is also possible. Additionally, NET and New Excellent Product (NEP) certified companies can apply for the World-Class Product Development Project.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing